Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2022 Earnings Call Transcript

Sravan Emany: Sure. Boris, this is Sravan. I’ll take that. Look, as with any proposed legislation, we’ll follow the developments closely here. We’re working with our partner, AbbVie, to assess any potential impact on our business. At this stage, it’s still — I think, a wide number of unknowns around certain aspects of this legislation. And thinking about the potential impact here to LINZESS, it’s important to note, we’ve been working with Medicare Part D for years. And for many years, the core aspect of our strategy has been to ensure broad coverage and patient access. So from a negotiation standpoint, from a discounting standpoint, none of this is new to us. And so I think we’re — we’ll come back to you when we have a better sense of what that looks like. But right now, I think that’s what we can say.

Thomas McCourt: And I think we’re reasonably confident. I mean, we’re providing very significant discounts currently to Medicare. I mean — which is the reason why we’re seeing some price erosion here because we are working closely with the Medicare payers as well as the commercial payers to ensure very broad payer access. So — could it have some impact? Yes. But I think of all the brands that are out there that they’re going to be focusing on, we’re already in the game and actively negotiating with the major payers. So we’ll have to wait and see, but I think we feel pretty good about the position we’re in.

Operator: And with no further questions, we will conclude today’s conference. Thank you for your participation, and you may now disconnect.